Suppr超能文献

TLR9 在慢性淋巴细胞白血病中的表达鉴定出一个促迁移亚群和新的治疗靶点。

TLR9 expression in chronic lymphocytic leukemia identifies a promigratory subpopulation and novel therapeutic target.

机构信息

Department of Clinical and Experimental Medicine, Brighton and Sussex Medical School, Falmer, United Kingdom.

Centre for Genomics and Computational Biology, Barts Cancer Institute, Queen Mary University of London, London, United Kingdom.

出版信息

Blood. 2021 Jun 3;137(22):3064-3078. doi: 10.1182/blood.2020005964.

Abstract

Chronic lymphocytic leukemia (CLL) remains incurable despite B-cell receptor-targeted inhibitors revolutionizing treatment. This suggests that other signaling molecules are involved in disease escape mechanisms and resistance. Toll-like receptor 9 (TLR9) is a promising candidate that is activated by unmethylated cytosine guanine dinucleotide-DNA. Here, we show that plasma from patients with CLL contains significantly more unmethylated DNA than plasma from healthy control subjects (P < .0001) and that cell-free DNA levels correlate with the prognostic markers CD38, β2-microglobulin, and lymphocyte doubling time. Furthermore, elevated cell-free DNA was associated with shorter time to first treatment (hazard ratio, 4.0; P = .003). We also show that TLR9 expression was associated with in vitro CLL cell migration (P < .001), and intracellular endosomal TLR9 strongly correlated with aberrant surface expression (sTLR9; r = 0.9). In addition, lymph node-derived CLL cells exhibited increased sTLR9 (P = .016), and RNA-sequencing of paired sTLR9hi and sTLR9lo CLL cells revealed differential transcription of genes involved in TLR signaling, adhesion, motility, and inflammation in sTLR9hi cells. Mechanistically, a TLR9 agonist, ODN2006, promoted CLL cell migration (P < .001) that was mediated by p65 NF-κB and STAT3 transcription factor activation. Importantly, autologous plasma induced the same effects, which were reversed by a TLR9 antagonist. Furthermore, high TLR9 expression promoted engraftment and rapid disease progression in a NOD/Shi-scid/IL-2Rγnull mouse xenograft model. Finally, we showed that dual targeting of TLR9 and Bruton's tyrosine kinase (BTK) was strongly synergistic (median combination index, 0.2 at half maximal effective dose), which highlights the distinct role for TLR9 signaling in CLL and the potential for combined targeting of TLR9 and BTK as a more effective treatment strategy in this incurable disease.

摘要

慢性淋巴细胞白血病(CLL)尽管 B 细胞受体靶向抑制剂彻底改变了治疗方法,但仍然无法治愈。这表明其他信号分子参与了疾病逃逸机制和耐药性。 Toll 样受体 9(TLR9)是一种有前途的候选物,可被未甲基化的胞嘧啶鸟嘌呤二核苷酸-DNA 激活。在这里,我们显示 CLL 患者的血浆中含有明显更多的未甲基化 DNA 比健康对照受试者的血浆(P <.0001),并且无细胞 DNA 水平与预后标志物 CD38、β2-微球蛋白和淋巴细胞倍增时间相关。此外,升高的无细胞 DNA 与首次治疗时间更短相关(危险比,4.0;P =.003)。我们还表明,TLR9 表达与体外 CLL 细胞迁移相关(P <.001),并且细胞内内体 TLR9 与异常表面表达(sTLR9;r = 0.9)强烈相关。此外,淋巴结衍生的 CLL 细胞表现出增加的 sTLR9(P =.016),并且配对的 sTLR9hi 和 sTLR9lo CLL 细胞的 RNA 测序显示 TLR 信号、粘附、运动和炎症相关基因在 sTLR9hi 细胞中的转录差异。在机制上,TLR9 激动剂 ODN2006 促进了 CLL 细胞迁移(P <.001),这是由 p65 NF-κB 和 STAT3 转录因子激活介导的。重要的是,自体血浆诱导了相同的效果,TLR9 拮抗剂可逆转这些效果。此外,高 TLR9 表达促进了 NOD/Shi-scid/IL-2Rγnull 小鼠异种移植模型中的嵌合体植入和快速疾病进展。最后,我们表明 TLR9 和 Bruton 酪氨酸激酶(BTK)的双重靶向具有强烈的协同作用(半最大有效剂量的中位组合指数为 0.2),这突出了 TLR9 信号在 CLL 中的独特作用以及联合靶向 TLR9 和 BTK 作为这种无法治愈的疾病的更有效治疗策略的潜力。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d85e/8176769/9647bd418e9b/bloodBLD2020005964absf1.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验